MCFAs provide a synergistic bactericidal effect in combination with antibiotics and bacteriophages to effectively treat antibiotic-resistant bacterial infections.

Researchers at the University of California, Davis have developed an innovative platform for creating genetically encoded fluorescent biosensors capable of 1) assessing the formation of GPCR homo and heterodimers, and 2) determining how dimerization impacts protomer conformation in response to ligands.The UC Davis IPN has developed a suite of ~24 biosensors based on GPCR dimers.Collectively called, dimerLights, these modular biosensors have the ability to identify novel dimeric drug targets and assess the impact of ligands on their conformations.In addition to the ~24 biosensors that UC Davis has already developed, the modular platform in principle can easily be adapted to enable the discovery and evaluation of broader GPCR homo/heterodimers than have been tested so far.

Researchers at the University of California, Davis have developed a therapy that combines bioactive lipids with antiretroviral drugs to accelerate viral suppression and promote gut mucosal repair in HIV treatment.

Researchers at the University of California, Davis, have created a technology that uses engineered polynucleotides to deliver both an antigen and an enzyme that breaks down amino acids. This approach is designed to boost long-lasting memory T-cell responses, providing stronger protection against infectious diseases and cancer.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Antibiotic resistance is a major issue in infectious disease treatment and prevention. In bacteria, the type III secretion system (T3SS) secretes effector proteins in the host cell, allowing the pathogen to infect. The T3SS is largely found on pathogens and not beneficial bacteria, so targeting the T3SS might have an advantage over using classic antibiotics, which disturb the beneficial human microbiome.

Researchers at the University of California, Davis have developed a technology that introduces vaccines that express macrophage-suppressing molecules to significantly enhance inflammatory T-cell functions for improved immune responses.

Researchers at the University of California, Davis have developed a potential therapeutic strategy aiming at disrupting intercellular communication of pathogens using quorum sensing molecules and silicon-based pharmacophores.

Progressive Multifocal Leukoencephalopathy (PML) is a devastating and often fatal demyelinating disease of the central nervous system caused by the reactivation of the JC virus (JCV). In immunocompromised patients, the absence of effective T cell surveillance allows the virus to infect and lyse oligodendrocytes, leading to irreversible neurological damage. UC Berkeley researchers have developed a method for discovering and engineering antigen-specific T cell receptors (TCRs) that specifically target JCV.

Researchers at the University of California, Davis have developed a vaccine platform utilizing non-replicating, metabolically active Cyborg Bacterial Pathogens to combat multi-antibiotic-resistant bacteria.

Researchers at the University of California, Davis have developed a computer-implemented method to identify viral mutations that enhance transmission and predict their prevalence in populations over time.